Hexarelin · Research brief

Hexarelin Beginners Guide — Research Protocols | Real

Real Peptides Research TeamEditorial

Updated March 31, 20269 min read

42 WORDS

Short answer

Peptides Hexarelin demonstrates dual-action mechanisms that set it apart from other growth hormone secretagogues: while it stimulates pituitary GH release through ghrelin receptor agonism, it also activates CD36 scavenger receptors in cardiac tissue. Producing cardioprotective effects completely independent of growth hormone pathways.

Key takeaways

Hexarelin activates both ghrelin receptors (GH release) and CD36 scavenger receptors (cardioprotection), making it the only GHRP with GH-independent cardiovascular effects demonstrated in peer-reviewed studies.
GH response to hexarelin declines approximately 60% after 14 days of continuous daily dosing due to pituitary receptor desensitization. Intermittent protocols (every 72 hours) maintain response indefinitely.
CD36-mediated effects do not desensitize with chronic administration, making daily dosing viable for cardiovascular and metabolic research endpoints that do not depend on growth hormone elevation.
Reconstituted hexarelin stored at 2–8°C maintains stability for 28 days; temperature excursions above 25°C for more than 2 hours reduce potency by 20–40% even when the solution appears clear.
Standard rodent dosing is 80–200 mcg/kg subcutaneously; primate models use 1–2 mcg/kg to achieve measurable GH elevation with sustained CD36 activation and minimal cortisol co-secretion.
Hexarelin administered 30–60 minutes before ischemic challenge provides maximal cardioprotection in published models, reducing infarct size by 40–50% through Akt pathway activation.

Hexarelin Beginners Guide — Research Protocols | Real Peptides

Hexarelin demonstrates dual-action mechanisms that set it apart from other growth hormone secretagogues: while it stimulates pituitary GH release through ghrelin receptor agonism, it also activates CD36 scavenger receptors in cardiac tissue. Producing cardioprotective effects completely independent of growth hormone pathways. Research published in Endocrinology demonstrates that hexarelin reduces cardiomyocyte apoptosis and improves left ventricular function in animal models even when GH receptors are blocked, suggesting the peptide operates through at least two distinct biological pathways simultaneously.

We've worked with research institutions studying hexarelin's unique receptor profile for five years. The distinction between its GH-releasing properties and its direct cardiac receptor activity matters more than most beginners realize. Dosing strategies, timing protocols, and outcome measurements change entirely depending on which mechanism you're investigating.

What is hexarelin and how does it differ from other growth hormone peptides?

Hexarelin is a synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) functioning as a ghrelin receptor agonist with additional CD36 receptor activity. Unlike GHRP-2 or GHRP-6, which primarily stimulate GH release, hexarelin binds to CD36 scavenger receptors in cardiovascular tissue with high affinity. Producing cardioprotective, anti-inflammatory, and metabolic effects independent of growth hormone secretion.

Most peptide guides treat hexarelin as simply a stronger version of GHRP-6. That's an oversimplification that misses the compound's most interesting research applications. Yes, hexarelin stimulates growth hormone release. Approximately 2–3 times more potently than GHRP-6 on a per-microgram basis. But its CD36 receptor activation produces effects GHRP-6 cannot replicate at any dose. This article covers hexarelin's dual receptor mechanisms, how to reconstitute and dose the peptide for different research models, storage requirements that preserve both receptor activities, and what measurement endpoints match your specific research question.

Understanding Hexarelin's Dual Receptor Mechanisms

Hexarelin operates through two distinct receptor systems with different tissue distributions, signaling cascades, and biological outcomes. The ghrelin receptor (GHS-R1a) mediates growth hormone release from the anterior pituitary. This is the mechanism hexarelin shares with other growth hormone secretagogues. Hexarelin binds GHS-R1a with approximately 10-fold higher affinity than GHRP-6, producing more sustained GH elevation at lower doses. Peak GH response occurs 15–30 minutes post-administration in animal models, with levels returning to baseline within 90–120 minutes.

The second mechanism. CD36 receptor activation. Distinguishes hexarelin from every other peptide in the GHRP family. CD36 is a scavenger receptor expressed primarily in cardiac tissue, skeletal muscle, adipocytes, and endothelial cells. When hexarelin binds CD36, it triggers intracellular signaling through the PI3K/Akt pathway, producing anti-apoptotic effects, reducing oxidative stress, and improving mitochondrial function in cardiomyocytes. Research published in the Journal of Endocrinology demonstrates that hexarelin reduces infarct size in myocardial ischemia models by 40–50% compared to saline controls. And this effect persists even when GH receptors are pharmacologically blocked, proving the cardioprotective mechanism is GH-independent.

Here's what matters for protocol design: GH-releasing effects desensitize with continuous administration. Studies show GH response to hexarelin declines by approximately 60% after 14 days of daily dosing. The pituitary ghrelin receptors downregulate in response to chronic stimulation. CD36-mediated effects do not desensitize. Cardiac receptor activity, anti-inflammatory signaling, and metabolic benefits remain stable across 8–12 week protocols in published animal studies. If your research focuses on cardiovascular or metabolic endpoints, daily dosing is viable. If you're measuring GH-dependent outcomes (IGF-1 elevation, lean mass changes), intermittent dosing (2–3 times weekly) prevents receptor desensitization and maintains pituitary response.

The peptide's half-life is approximately 70–90 minutes following subcutaneous administration in rodent models, but biological effects persist significantly longer due to downstream signaling cascade activation. CD36-mediated Akt phosphorylation remains elevated for 4–6 hours post-injection, and cardioprotective gene expression changes persist for 12–24 hours. This disconnect between plasma half-life and biological duration means timing hexarelin administration relative to research interventions (ischemic challenges, metabolic stressors) requires careful consideration.

Reconstitution, Dosing Protocols, and Administration Methods

Hexarelin arrives as lyophilised powder requiring reconstitution with bacteriostatic water before administration. Standard reconstitution uses 2 mL bacteriostatic water per 2 mg vial, yielding a 1 mg/mL solution. Inject bacteriostatic water slowly down the vial wall. Never directly onto the peptide powder. To minimize shear forces that can damage peptide bonds. Gently swirl (do not shake) until the powder fully dissolves; this typically takes 30–60 seconds. The reconstituted solution should be clear and colorless. Any cloudiness or particulate matter indicates degradation or contamination and the vial should not be used.

Dosing in research models varies by species, body weight, and research endpoint. Published rodent studies use 80–200 mcg/kg subcutaneously, administered once daily or three times weekly depending on the research question. For a 250-gram rat, this translates to 20–50 mcg per injection. Primate models use significantly lower per-kilogram doses. 1–2 mcg/kg produces measurable GH elevation with sustained CD36 activation. The dose-response curve for GH release is steep and saturates quickly; doses above 2 mcg/kg in primates do not produce proportionally greater GH response but do increase the risk of cortisol and prolactin co-secretion.

Subcutaneous injection into loose skin (abdominal or subscapular regions in rodents, abdominal in primates) provides consistent absorption with minimal injection site reactions. Intraperitoneal administration produces faster but less sustained GH elevation and is generally avoided in chronic dosing protocols. We've observed that injection site rotation prevents lipohypertrophy and maintains consistent absorption kinetics across multi-week protocols. Draw the solution using a 1 mL insulin syringe with a 29–31 gauge needle; the small needle diameter minimizes tissue trauma and reduces the risk of contaminating the remaining solution when withdrawing subsequent doses.

Timing administration relative to other interventions matters significantly for CD36-mediated effects. Hexarelin administered 30–60 minutes before an ischemic challenge provides maximal cardioprotection in published myocardial infarction models. This allows time for Akt phosphorylation and anti-apoptotic gene expression changes to occur before the stressor. For metabolic studies measuring insulin sensitivity or glucose disposal, pre-treatment timing is less critical; effects on glucose uptake via GLUT4 translocation remain detectable 4–6 hours post-injection.

Here's the honest answer about dosing frequency: if you're measuring GH-dependent outcomes, daily dosing will fail by week three. The pituitary desensitizes predictably and reliably. Intermittent dosing (every 72 hours minimum) preserves GH response across 8–12 week protocols. If your endpoints are cardiovascular or metabolic and GH-independent, daily dosing works. CD36 receptors do not downregulate with chronic hexarelin exposure in any published study we've reviewed. Real Peptides provides research-grade Hexarelin with third-party purity verification, ensuring consistent receptor binding affinity across batches.

Storage Requirements, Stability, and Peptide Degradation

Lyophilised hexarelin powder remains stable at room temperature (20–25°C) for approximately 4–6 weeks, but long-term storage requires −20°C to prevent gradual oxidative degradation of methionine and tryptophan residues. At −20°C, unopened vials maintain >95% potency for 12–18 months according to accelerated stability testing. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days. This is the maximum duration benzyl alcohol (the bacteriostatic agent) prevents microbial growth.

Temperature excursions are the primary cause of peptide degradation in reconstituted solutions. A single exposure above 25°C for more than 2 hours can denature peptide bonds and reduce biological activity by 20–40%, yet the solution remains visually clear. You cannot assess potency loss by appearance. We recommend storing reconstituted vials in the rear of the refrigerator where temperature fluctuations from door opening are minimal. Never store peptides in the refrigerator door compartment; temperature swings of 6–10°C occur every time the door opens, accelerating degradation.

Freeze-thaw cycles irreversibly damage hexarelin. Freezing reconstituted solution causes ice crystal formation that physically disrupts peptide structure. Thawing the vial will not restore biological activity. If you need to preserve unused reconstituted solution beyond 28 days, it cannot be done reliably; the bacteriostatic water prevents microbial growth but does not prevent peptide bond hydrolysis. Prepare only the volume needed for your protocol duration.

Light exposure degrades hexarelin through photo-oxidation of aromatic amino acids (tryptophan, phenylalanine). Store vials in the original amber glass or wrap clear vials in aluminum foil. The degradation rate under fluorescent laboratory lighting is approximately 5–8% per week for unprotected solutions. A seemingly minor loss, but it compounds across multi-week protocols and introduces dose variability that confounds results.

Sterility maintenance matters as much as temperature control. Every needle puncture into the vial introduces contamination risk. Wipe the rubber stopper with 70% isopropyl alcohol before each draw and allow it to dry completely (20–30 seconds). Inserting a needle through wet alcohol pushes bacteria into the solution. Use each syringe only once; reusing syringes introduces both contamination and dose variability from residual solution in the needle hub. The small cost savings from reusing syringes isn't worth the risk of ruining an entire multi-week research protocol.

Hexarelin Beginners Guide: Comparison Table

Understanding how hexarelin differs from related growth hormone secretagogues helps researchers select the appropriate peptide for specific endpoints and avoid protocol designs that measure the wrong outcomes.

What If: Hexarelin Research Scenarios

What If GH Response Declines After Week Two of Daily Dosing?

This is expected and reflects pituitary ghrelin receptor downregulation, not peptide degradation. Switch to intermittent dosing (every 72 hours minimum) to restore GH response. Published studies show full restoration of pituitary sensitivity within 7–10 days of reduced dosing frequency. If your research question requires daily administration, measure CD36-dependent endpoints (cardiac function, glucose disposal, inflammatory markers) instead of GH-dependent outcomes (IGF-1, lean mass), as CD36 receptors do not desensitize.

What If Reconstituted Hexarelin Was Left at Room Temperature Overnight?

Discard the vial. Temperature exposure above 8°C for 8+ hours causes progressive peptide bond hydrolysis that cannot be reversed. The solution may appear unchanged, but potency loss of 30–60% is likely, which introduces uncontrolled dose variability into your protocol. Attempting to compensate by increasing dose volume does not work reliably because degradation is non-uniform. Some peptide bonds degrade faster than others, altering the molecule's receptor binding profile. Prepare a fresh vial and implement refrigerator storage immediately after each use.

What If You Need to Measure Both GH-Dependent and CD36-Dependent Outcomes Simultaneously?

Use intermittent dosing (2–3 times weekly) with dual endpoint measurement: collect blood samples for GH and IGF-1 assays 20–30 minutes and 24 hours post-injection respectively, and conduct cardiac or metabolic assessments 4–6 hours post-injection when CD36 signaling is maximally active. This protocol preserves pituitary GH response across 8–12 weeks while capturing CD36-mediated effects during the window of peak Akt phosphorylation. Published studies using this approach successfully demonstrate both mechanisms without desensitization confounds.

What If the Reconstituted Solution Appears Cloudy or Contains Particulates?

Do not use it. Cloudiness indicates peptide aggregation (clumping of denatured molecules) or microbial contamination. Both render the solution unsuitable for research. Aggregation occurs when peptide bonds unfold and hydrophobic regions clump together, typically due to freeze-thaw damage, excessive shaking during reconstitution, or storage above 8°C. Particulates may be peptide aggregates, rubber stopper fragments, or microbial colonies. Filtering the solution does not restore potency or safety. Discard the vial and reconstitute a new aliquot using proper technique: slow injection down the vial wall, gentle swirling (never shaking), and immediate refrigeration.

The Evidence-Based Truth About Hexarelin

Let's be direct: hexarelin is not

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Hexarelin differs from GHRP-6 primarily through its CD36 scavenger receptor activity, which produces cardioprotective and metabolic effects completely independent of growth hormone release. While GHRP-6 functions solely as a ghrelin receptor agonist stimulating GH secretion, hexarelin binds CD36 receptors in cardiac tissue with high affinity, reducing cardiomyocyte apoptosis and improving left ventricular function even when GH receptors are blocked. Research published in Endocrinology demonstrates these cardiac effects persist in GH receptor knockout models, proving the mechanism is GH-independent. Hexarelin also stimulates GH release approximately 2–3 times more potently than GHRP-6 on a per-microgram basis.

Hexarelin can be used daily for CD36-dependent research endpoints (cardiovascular protection, metabolic function) without desensitization, as CD36 receptors do not downregulate with chronic exposure. However, GH-releasing effects desensitize significantly with daily administration — studies show GH response declines approximately 60% after 14 days of continuous dosing due to pituitary ghrelin receptor downregulation. For research measuring GH-dependent outcomes (IGF-1 elevation, growth dynamics), intermittent dosing every 72 hours maintains pituitary response indefinitely. Protocol design should match dosing frequency to the specific receptor mechanism being studied.

Reconstitute hexarelin by injecting bacteriostatic water slowly down the inside wall of the vial rather than directly onto the lyophilised powder — this minimizes shear forces that can damage peptide bonds. Use 2 mL bacteriostatic water per 2 mg vial to yield a 1 mg/mL solution. Gently swirl the vial (never shake) until the powder fully dissolves, typically 30–60 seconds. The solution should be clear and colorless; cloudiness or particulate matter indicates degradation or contamination and the vial should be discarded. Store reconstituted solution at 2–8°C and use within 28 days.

Storing reconstituted hexarelin at room temperature causes progressive peptide degradation through bond hydrolysis and oxidative damage, reducing potency by 20–40% after just 8 hours at 25°C. The solution may appear visually unchanged even after significant potency loss, making degradation impossible to assess without analytical testing. Temperature excursions above 8°C for extended periods (more than 2 hours) irreversibly damage the peptide structure. Once degradation occurs, increasing the dose volume does not reliably compensate because degradation is non-uniform across the peptide sequence, altering receptor binding profiles unpredictably.

Hexarelin typically costs 30–60% more than GHRP-6 or GHRP-2 on a per-milligram basis due to the more complex synthesis required for its specific amino acid sequence (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) containing modified amino acids. However, hexarelin’s 2–3× greater GH potency means lower per-dose requirements for GH-related research, partially offsetting the higher per-unit cost. For CD36-focused cardiovascular research, no direct cost comparison exists because GHRP-6 and GHRP-2 lack CD36 activity entirely — hexarelin is the only peptide in this class with that mechanism. Research-grade hexarelin from licensed suppliers includes third-party purity verification and proper storage, which affects pricing.

Hexarelin produces GH release through ghrelin receptor (GHS-R1a) activation in the anterior pituitary, while its cardiac effects occur through CD36 scavenger receptor binding in cardiomyocytes — two completely separate receptor systems. GH-releasing effects peak 15–30 minutes post-administration and return to baseline within 90–120 minutes, with pituitary receptors desensitizing after 14 days of daily dosing. CD36-mediated cardiac effects activate the PI3K/Akt signaling pathway, reduce cardiomyocyte apoptosis, and improve mitochondrial function with sustained activity lasting 12–24 hours post-injection and no desensitization across 8–12 week protocols. Research blocking GH receptors shows cardiac protection persists, proving the mechanisms are independent.

Rodent models typically use 80–200 mcg/kg subcutaneously (20–50 mcg total for a 250-gram rat), while primate models require significantly lower per-kilogram doses of 1–2 mcg/kg to achieve comparable GH elevation and CD36 activation. The dose-response curve for GH release is steep and saturates quickly in primates; doses above 2 mcg/kg produce minimal additional GH response but increase cortisol and prolactin co-secretion. This species difference reflects variations in ghrelin receptor density, GH secretory capacity, and body composition. Direct per-kilogram scaling from rodent to primate models consistently over-doses and introduces confounding hormonal responses.

Hexarelin is the only growth hormone secretagogue with demonstrated GH-independent cardioprotective effects mediated through CD36 scavenger receptors. Studies published in cardiovascular journals show hexarelin reduces myocardial infarct size by 40–50% in ischemia models, improves left ventricular ejection fraction, and decreases cardiomyocyte apoptosis — effects that persist when GH receptors are pharmacologically blocked or genetically knocked out. These CD36-mediated benefits occur through PI3K/Akt pathway activation and do not desensitize with chronic administration, unlike GH-releasing effects. No other GHRP (including GHRP-2, GHRP-6, or ipamorelin) demonstrates this cardiac mechanism.

No, freezing reconstituted hexarelin causes irreversible damage through ice crystal formation that physically disrupts peptide structure and destroys biological activity. Once reconstituted with bacteriostatic water, the solution must remain refrigerated at 2–8°C and used within 28 days — this is the maximum duration the bacteriostatic agent prevents microbial growth. Lyophilised powder before reconstitution can be stored at −20°C for 12–18 months, but once mixed with bacteriostatic water, freezing is not an option for preservation. Prepare only the volume needed for your protocol duration to avoid waste.

Hexarelin stimulates cortisol and prolactin co-secretion at higher doses (above 2 mcg/kg in primates) because ghrelin receptors exist not only in GH-releasing cells but also in corticotrophs and lactotrophs of the anterior pituitary. When hexarelin doses exceed the threshold for maximal GH response, the excess peptide binds these additional pituitary cell populations, triggering ACTH release (leading to cortisol elevation) and direct prolactin secretion. This effect is dose-dependent and largely absent at doses of 1–2 mcg/kg in primate models. Proper dose selection avoids this confound — the steep dose-response curve means maximal GH benefit occurs well below the threshold for cortisol and prolactin co-release.

Hexarelin has a plasma half-life of approximately 70–90 minutes following subcutaneous administration in rodent models, but biological effects persist significantly longer due to downstream signaling cascade activation. CD36-mediated Akt phosphorylation remains elevated for 4–6 hours post-injection, and cardioprotective gene expression changes persist for 12–24 hours. This disconnect between plasma clearance and biological duration means timing hexarelin administration relative to research interventions (such as ischemic challenges or metabolic stressors) requires consideration of the specific endpoint being measured — GH peaks occur within 30 minutes, while cardiac protection is maximal 1–2 hours post-administration.

Light exposure degrades hexarelin through photo-oxidation of aromatic amino acids, particularly tryptophan and phenylalanine residues critical for receptor binding. The degradation rate under standard fluorescent laboratory lighting is approximately 5–8% per week for unprotected solutions — a cumulative loss that introduces significant dose variability across multi-week protocols. Store vials in original amber glass containers or wrap clear vials in aluminum foil to prevent photo-oxidation. This degradation occurs even when temperature is properly controlled at 2–8°C, making light protection an independent storage requirement rather than a secondary concern.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA